Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nivolumab and NSCLC

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    96 result(s) found for: Nivolumab and NSCLC. Displaying page 2 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2019-002986-36 Sponsor Protocol Number: NIBIT-ML-1 Start Date*: 2020-06-19
    Sponsor Name:FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI
    Full Title: A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1
    Medical condition: MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005741-31 Sponsor Protocol Number: AIO-YMO/TRK-0415 Start Date*: 2016-12-02
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC
    Medical condition: metastatic non-squamous Non-Small Cell Lung Cancer (Lung adenocarcinoma metastatic and Large cell lung cancer metastatic)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069730 Large cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064049 Lung adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003731-37 Sponsor Protocol Number: CA209-907 Start Date*: 2017-10-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label, single-arm Phase II Safety Study of Nivolumab in Subjects with Advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior syst...
    Medical condition: Advanced or metastatic non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-000137-17 Sponsor Protocol Number: BA3021-001 Start Date*: 2022-09-27
    Sponsor Name:BioAtla
    Full Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002423-29 Sponsor Protocol Number: INCB24360-204 Start Date*: 2017-07-13
    Sponsor Name:incyte Corporation
    Full Title: A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers
    Medical condition: Selected advanced cancers, including metastatic and/or unresectable solid tumors including NSCLC, melanoma,adenocarcinoma of the colon or rectum , recurrent squamous cell carcinoma of the head and ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002478-29 Sponsor Protocol Number: CA224-063 Start Date*: 2019-11-27
    Sponsor Name:University Hospital Essen
    Full Title: Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung)
    Medical condition: non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003731-20 Sponsor Protocol Number: CEGF816X2201C Start Date*: 2015-05-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult...
    Medical condition: EGFR mutated non-small cell lung cancer and EGFR wild-type non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000958-98 Sponsor Protocol Number: 2017-1-39-007 Start Date*: 2020-08-07
    Sponsor Name:Centre Régional de lutte contre le Cancer Eugène Marquis
    Full Title: A phase II trial evaluating conformational intensity modulated radiotherapy with concomitant nivolumab followeb by nivolumab for patients with locally advanced non-small cell lung cancer
    Medical condition: Patient having locally Advanced Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003334-25 Sponsor Protocol Number: Uni-Koeln-2785 Start Date*: 2017-01-26
    Sponsor Name:University of Cologne
    Full Title: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
    Medical condition: Patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and patients with Small cell lung cancer (SCLC) after failure of platinum-based first-line therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041070 Small cell lung cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001043-41 Sponsor Protocol Number: 516-005 Start Date*: 2020-11-03
    Sponsor Name:Mirati Therapeutics, Inc.
    Full Title: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Plat...
    Medical condition: Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) HU (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004502-93 Sponsor Protocol Number: CA209-026 Start Date*: 2014-04-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer
    Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) SE (Completed) FI (Completed) CZ (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) RO (Ongoing) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-005187-34 Sponsor Protocol Number: CCR4644 Start Date*: 2017-09-11
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: Stereotactic body radiotherapy with immunotherapy in early stage non-small cell lung cancer: tolerability and lung effects
    Medical condition: Non small-cell lung cancer (NSCLC) Stage: T1-3( ≤5cm)N0M0)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002472-14 Sponsor Protocol Number: CA209-057 Start Date*: 2012-12-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC)
    Medical condition: Non-Squamous cell Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) HU (Completed) CZ (Completed) IT (Completed) PL (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003304-43 Sponsor Protocol Number: INCB24360-309 Start Date*: 2018-04-12
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat with Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small C...
    Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000367-33 Sponsor Protocol Number: CA209-9GW Start Date*: 2017-08-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors
    Medical condition: Advanced or metastatic solid tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000135-23 Sponsor Protocol Number: BA3011-002 Start Date*: 2023-02-13
    Sponsor Name:BioAtla Inc.
    Full Title: A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression On or Are Intol...
    Medical condition: Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001585-42 Sponsor Protocol Number: CA209-8KX Start Date*: 2019-01-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy
    Medical condition: The study population will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: non-small cell lung cancer (NSCLC); renal ce...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001743-12 Sponsor Protocol Number: INCB24360-208 Start Date*: 2018-07-04
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Maligna...
    Medical condition: Phase 1 (Dose Escalation): Advanced or metastatic solid tumors. Phase 2 (Dose Expansion): Advanced or metastatic non–small cell lung cancer (NSCLC), unresectable or metastatic melanoma (MEL) and r...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027150 Melanoma malignant LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-005115-41 Sponsor Protocol Number: TG4010.24 Start Date*: 2017-11-29
    Sponsor Name:Transgene S.A.
    Full Title: A phase II study evaluating the efficacy and the safety of first-line chemotherapy combined with TG4010 and nivolumab in patients with advanced non-squamous Non-Small-Cell Lung Cancer (NSCLC)
    Medical condition: Stage IIIB-IV non small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000340-26 Sponsor Protocol Number: CA027-002 Start Date*: 2018-10-31
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
    Medical condition: Advanced Cancers
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 10 19:42:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA